Answer
The treatment targets a pathway driven by PIK3CA mutations, and the licence requires confirmation of an eligible mutation in tumour tissue or plasma.
Sources for this answer
- Itovebi 3 mg & 9mg film-coated tablets — Current selected SmPCemc · Summary of Product Characteristics
General medicine information. Follow the instructions for your own medicine and speak to a pharmacist or clinician about your individual circumstances.